Kripthonite Therapeutics ApS
Saving lives by eliminating hypoxic cancer cells
Rewriting the Rules of Cancer Therapy
At Kripthonite Therapeutics, we are pioneering a bold new approach to cancer treatment by targeting one of the most formidable challenges in oncology: hypoxic tumor cells. These cells thrive in low-oxygen environments, making them highly resistant to conventional therapies like chemo-, radio-, and immunotherapy.
​
Our lead compound, PH1154, is the first and most advanced candidate in a new class of Hypoxia-Targeting Macrocycles (HTMCs) – a novel therapeutic platform designed to selectively eliminate hypoxic cancer cells by disrupting their unique energy metabolism. This precision mechanism leads to rapid and selective cell death within hours, weakening the tumor’s defenses and enhancing the effectiveness of other treatments.
In preclinical models of hard-to-treat tumors, PH1154 has demonstrated remarkable synergy with radiotherapy. These results underscore the transformative potential of PH1154 to unlock deeper, more durable responses in cancer therapy.
​
We believe PH1154 represents a paradigm shift in oncology – one that could significantly improve outcomes for patients facing the most aggressive and treatment-resistant cancers.